New Investments
South African Insurtech Naked Raises $38 Million in Series B2 Funding
Naked, a South African insurtech company, has successfully raised $38 million in a Series B2 funding round.
This latest funding will enable Naked to advance its automation and artificial intelligence capabilities, expand its product portfolio, extend its market presence, and bolster advertising efforts to grow its customer base.
The Series B2 round follows the company’s earlier Series B funding in February 2023, which secured $17 million from investors such as IFC, Yellowwoods, Hollard, and DEG.
Founded in 2018 by actuaries Alex Thomson, Sumarié Greybe, and Ernest North, Naked has revolutionized the insurance industry with its fully digital platform.
Related Articles
Register Now
Empower Africa Times Newsletter
Share :
“We are delighted to partner with ISA to support the development of solar energy in Africa,” said Alain Ebobissé, CEO of Africa50. “This partnership will help to accelerate the deployment of solar energy in Africa and improve the lives of millions of Africans,” he added.
You may also like…
Egypt’s MoneyFellows Raises $13 Million to Boost Expansion and Reinvent Group Savings in Africa
Egyptian fintech startup MoneyFellows has secured $13 million in a pre-Series C investment round to support its growth beyond Egypt and enhance its digital savings platform.
Ventures Platform Raises $64 Million in First Close of $75 Million Pan-African Fund II
African seed-stage investor Ventures Platform has announced that the first close of its second institutional vehicle, VP Pan‑African Fund II, has reached US $64 million, with a target of reaching US $75 million at final close.
African Development Bank and Biovac Sign $15 Million Agreement to Advance Africa’s First End-to-End Cholera Vaccine Production
The African Development Bank (AfDB) has finalized a loan of up to $15 million to South Africa’s Biologicals and Vaccines Institute (Biovac), supporting the construction of a new multi-vaccine manufacturing facility in Cape Town that is expected to strengthen Africa’s vaccine production capacity and reduce the continent’s heavy dependence on imported vaccines.